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introduction
biochemical and physioloGical aspects
Cardiac troponins – C, I and T – form part of the troponin 
complex which is involved in the regulation of the calcium-
mediated interaction of actin and myosin in myocytes.1 Each 
troponin has a different role in the above mentioned complex. 
Troponin C is involved in binding calcium, troponin I inhibits 
interaction of actin to myosin, while Troponin T binds to 
tropomyosin and facilitates muscle contraction.1
Both skeletal as well as cardiac muscle types express 
troponin C, however the amino acid sequences of troponin I 
and troponin T are unique to cardiac muscle. It is the specificity 
of these latter troponins to cardiac muscle that allowed for 
the development of quantitative assays that detect elevations 
of troponins in the serum once released by damaged cardiac 
muscle tissue.1
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The majority of Troponin I and C form part of the contractile 
apparatus of the muscle myofibril. A small fraction of the 
troponins is however free in the cytoplasm. This fact explains 
the relatively biphasic rise in serum troponin. The initial rise 
corresponds to the release of free cytoplasmic troponin. This is 
subsequently followed by a second rise – that corresponds to the 
dispersion of the myofibril-bound troponin complexes.1
Keeping the above mechanisms in mind, one notes that 
any form of damage to cardiac muscle may result in the release 
of the above proteins into the bloodstream. As acute coronary 
syndromes are the commonest cause of myocardial damage, the 
detection of elevated levels of troponin levels in the serum are 
often attributed to such events.2
discussion
troponin: the ideal cardiac biomarKer
The earliest cardiac biomarkers used to detect myocardial 
ischemia included aspartate aminotransferase and lactate 
dehydrogenase isoenzymes, however these biomarkers were found 
to be poorly specific in view of the fact that they have a wide tissue 
ditribution.1 Eventually,  creatine kinase (CK)-MB isoenzyme 
assays were posited as the gold standard investigations in the 
diagnosis of acute coronary syndromes (ACS). 
CK-MB, whilst more specific for cardiac muscle, still 
constitutes around 1-3% of the CK found in skeletal muscle. It 
is also present in a small fraction in other organs such as the 
prostate, uterus and small bowel. Therefore in the setting of major 
injury to any of the above organs the specificity of CK in detecting 
myocardial damage is reduced.1
CK-MB has gradually been sidestepped by cardiac troponin 
assays, which have ever since their initial use for the diagnosis 
of ACS, become more and more sensitive.3 Nowadays the 
cardiac troponin testing is the preferred diagnostic test for ACS 
particularly for non-ST segment-elevation myocardial infarction 
(NSTEMI). The results from cardiac troponin testing guide the 
decision for the adequate intervention in patients in whom the 
diagnosis of ACS is not obvious from the clinical presentation and 
the findings on ECG.3 
Troponin I and T, when compared to other biomarkers, have 
both the highest sensitivity and specificity for cardiac ischemia.1 
Between 1995 and 2007, the limit of detection of cardiac troponins 
fell from 0.5ng/mL to 0.006ng/mL, accounting for approximately a 
hundred-fold improvement in analytic sensitivity.3
However, whilst the increasing sensivity of troponin assays are 
allowing us to recognise and treat ACS earlier, the ever increasing 
Figure 1: Schematic representation of the thin filament of the 
muscle myofibrils. Myosin is the principal protein from which the 
thick filaments are composed
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sensitivity of these biomarkers is in itself inevitably associated 
with a reduction in the specificity of the test.3
The value of troponins in the diagnosis of ACS
Acute myocardial infarction (MI) is defined as necrosis of 
myocardial tissue. The diagnosis nowadays requires that there 
must be a rise or fall in troponin levels with at least one value 
above the 99th percentile of the upper reference limit of the 
normal healthy population as defined by European Society of 
Cardiology in 2007.1 In addition, there should be at least one of 
the following:
1. ECG changes indicative of ischemia (e.g. new ST/T wave 
changes or new LBBB)
2. Symptoms suggestive of ischemia, e.g. chest pain, 
diaphoresis, nausea, SOB or loss of consciousness
3. Imaging studies showing evidence of new wall motion 
abnormalities/loss of viable myocardium.1
In the past, the major limitation of cardiac troponins in 
aiding diagnosis of ACS was the fact that in the first few hours 
after an MI, plasma troponin levels would still be undetectable 
– secondary to the delayed increase in circulating levels of 
cardiac troponins. Generally the diagnosis would depend on 
monitoring the patient and taking serial blood samples over a 
6-12 hour period.2 Nowadays with the high sensitivity troponin 
assays which are becoming available, it is recommended that 
the second specimen can be collected at 2-3 hours from the first 
specimen taken at presentation.3 This is a huge improvement 
as the longer the wait before a diagnosis is made (and any 
applicable intervention) the greater the morbidity and mortality. 
However, as mentioned earlier, the greater sensitivity of the 
troponin assays means that the number of patients with 
detectable Troponin elevations in the emergency department 
or other in-hospital settings, will increase as a result. This poses 
greater challenges on physicians to make a differential diagnosis. 
Non-ischemic causes of troponin elevation should thus always 
be kept in mind. One should always refer to the clinical picture, 
ECG and other available investigations.2
Non-ACS causes of elevated Troponins
Many cardiovascular and non-cardiovascular states are 
associated with elevated troponin levels. Atrial fibrillation, 
supraventricular tachycardias, heart failure, myocarditis and 
cardiac contusion are among the non-ACS causes of increased 
troponin levels. 
Increased toponins levels are also noted to be present in 
conditions such as Chronic obstructive pulmonary disease 
(COPD) and acute pulmonary embolism. These conditions 
cause right heart strain which in turn might explain the link 
with the elevated troponin levels. End-stage renal disease 
(ESRD) is also commonly associated with an elevated troponin 
level. In fact, it is thought that if all the patients with ESRD 
were to have their troponin levels measured, in over 50% of the 
patients they would be elevated. This is often attributed to the 
impaired excretion of troponin, however it might also be the 
result of small areas of clinically silent myocardial necrosis.2
Intracranial pathology is another non-cardiac cause of 
elevated troponin levels. Not uncommonly, patients with 
intracranial hemorrhages (e.g. subarachnoid haemorrhages) 
and acute strokes are found to have elevated troponin 
levels. Furthermore these individuals may also have 
electrocardiographic changes, such as cardiac rythm 
disurbances, which may further confuse the picture. One 
theory for the above is that myocardial ischemia develops 
pursuant to any pre-existing cardiac tachycardia/hypertension. 
Howwver, nowadays the most widely accepted explanation is the 
“cathecolamine hypothesis”. It is believed that acute brain injury 
causes a massive release of cathecolamines (norepinephrine) 
from sympathetic nerve terminals innervating the myocardium. 
This subsequently leads to myocyte necrosis and contractile 
dysfunction resulting in the ECG changes and troponin release 
into the plasma.2
Non-thrombotic causes of elevated troponin levels1. 
1. Direct myocardial damage
	 •	Cardiac	contusions
	 •	Direct	current	cardioversion
	 •	Cardiac	infiltrative	disorders
	 •	Chemotherapy
	 •	Myocarditis
	 •	Cardiac	transplantation	(immune-mediated	reactions)
2.  Myocardial strain
	 •	COPD
	 •	CHF
	 •	Acute	pulmonary	embolism
3.  Chronic renal insufficiency
4.  Intracranial pathology (subarachnoid haemorrhages/acute 
stroke)
5.  Demand ischemia (in absence of ACS)
	 •	Left	ventricular	hypertrophy
	 •	Anaemia
	 •	Hypotension
	 •	Hypovolaemia
	 •	Atrial	Fibrillation/Supraventricular	tachycardia
The Prognostic role of Cardiac Troponins
Apart from their diagnostic role, cardiac troponins also yield 
prognostic information. Patients having clinical evidence of 
ischemia and high levels of troponin in the circulation tend to 
have a worse prognosis. Studies have shown that peak troponin 
T levels in the circulation actually correlate well with the infarct 
size. The greater the extent of the troponin rise, the poorer the 
prognosis.1
conclusion
Early detection of MI is crucial in ensuring better outcomes. 
Troponin assays are essential in establishing an earlier 
diagnosis. However, the ever-increasing sensitivity of these 
assays is associated with a decrease in their specificity. One 
should consider the clinical picture as well as other available 
investigations, and always take at least two serial troponin 
readings. ref
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